Advisory Board
The Gene is supported by a dedicated advisory board, each member bringing specialized expertise in gene therapy, regenerative medicine, and biotech finance. Our advisors are committed to ensuring that our gene therapies are designed, developed, and delivered to the highest standards of safety, efficacy, and accessibility. Together, they provide an impartial, science-driven foundation that prioritizes quality and patient care at every step.
Denisa Rensen
Denisa Rensen is a regenerative medicine practitioner with a strong foundation in biocompatible therapies. Her clinical approach is rooted in aligning treatments with the body’s intrinsic capacities for repair and renewal, focusing on therapies that work harmoniously with human biochemistry and biophysics. With a long career in biologics, Denisa brings a patient-centered perspective, emphasizing approaches that support and respect the body's natural processes.
As an advisor to The Gene, Denisa provides guidance on patient care and experience, ensuring that therapies are both accessible and delivered with precision. Her commitment to compassionate, science-driven medicine helps to shape a therapeutic experience that prioritizes patient understanding and trust. With a deep knowledge of integrative medicine, she is instrumental in maintaining The Gene’s focus on quality care throughout the treatment journey.
Alexander Paziotopoulos
Dr. Alexander Paziotopoulos, MD, brings over two decades of experience in anti-aging and regenerative medicine, known for his solution-oriented, patient-focused approach. As the founder of The Pazio Institute in Chicago, Dr. Paziotopoulos combines cutting-edge treatments with preventive strategies to help patients achieve long-term vitality. His expertise in anti-aging, functional medicine, and regenerative therapies has positioned him as a trusted voice in the industry, advocating for a comprehensive, forward-thinking approach to health.
At The Gene, Dr. Paziotopoulos advises on the clinical applications of gene therapies, ensuring their safety and efficacy in patient care. His emphasis on precision and his hands-on approach in his own practice inform his guidance here, helping to shape treatments that are not only effective but also considerate of individual patient needs. His expertise in medical engineering and personalized medicine brings a valuable clinical perspective to The Gene’s offerings.
Senmaru Hrncirik Maruyama
Senmaru Hrncirik-Maruyama contributes a unique blend of financial acumen and a deep interest in biotechnology and longevity science. Currently studying at the Stockholm School of Economics, Senmaru is building his expertise in finance while spearheading initiatives that explore the intersections of AI, biotech, and health. His early exposure to the field and dedication to sustainable health innovation bring a forward-thinking approach to The Gene’s strategic goals.
As a financial advisor, Senmaru supports The Gene’s mission to provide accessible gene therapies without compromising on quality. His role ensures that financial and operational frameworks are both sustainable and patient-centered, allowing The Gene to offer advanced therapies that are accessible, affordable, and of the highest standards. His fresh perspective on biotech finance and commitment to longevity science are integral to the company’s evolving approach to therapeutic innovation.
Brian Manning Delaney
Brian Manning Delaney is a widely respected figure in the longevity and gene therapy field, known for his expertise in designing science-based approaches to healthy aging. With extensive experience in organizations like the Calorie Restriction Society International and the Vitality in Aging (VIA) Research Group, Brian has dedicated his career to advancing rigorous, evidence-backed strategies in longevity research. His work as President of the Age Reversal Network and involvement in clinical trials underscores his commitment to careful, impactful research.
In his advisory role at The Gene, Brian provides impartial oversight on scientific research and gene development. His insights into gene therapies for brain health, particularly for APOE-ε4 carriers, are essential to ensuring the therapies we offer are both effective and aligned with the latest scientific advancements. Brian’s background in venture capital with Emergency Longevity Ventures further adds a strategic layer to The Gene, supporting innovations in age-related health solutions with an eye toward sustainable impact.
